GlassScriptPhysician profile
Sara A Marshall
NPI 1730836669
$2,103.47
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $386 · 2023: $1,111 · 2024: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $307.13 | 2022-2024 | |
| Boston Scientific Corporation | $262.43 | 2023-2024 | Watchman Access System |
| Merck Sharp & Dohme LLC | $229.93 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $182.59 | 2022-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $162.06 | 2022-2024 | Eliquis |
| Edwards Lifesciences Corporation | $154.75 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $147.68 | 2022-2024 | |
| Haemonetics Corporation | $115.30 | 2024 | Teg6s Hemostasis System |
| Janssen Pharmaceuticals, INC | $105.50 | 2022-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $60.69 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $57.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.72 | 2022-2024 | Jardiance |
| Chiesi USA, INC. | $52.46 | 2022-2024 | Kengreal |
| Esperion Therapeutics, INC. | $45.84 | 2023 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.30 | 2022-2023 | Lifevest |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $34.10 | 2024 | Assure Wcd |
| Medtronic, INC. | $28.47 | 2023 | Linq II |
| Kiniksa Pharmaceuticals, LTD. | $27.24 | 2022-2023 | Arcalyst |
| Amgen INC. | $20.08 | 2022 | |
| Genzyme Corporation | $18.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.